Aggregated News
Salt Lake City-based Myriad Genetics has settled one of a number of lawsuits over gene-related patents it filed against competitors who sprang up after the U.S. Supreme Court invalidated parts of those patents.
Myriad Genetics said Friday it had reached a settlement with Houston-based Gene by Gene Ltd., but Myriad vowed to continue legal battles against other competitors trying to jump into the market.
As part of the settlement, Gene by Gene will stop selling or marketing tests in the United States for the BRCA1 and BRCA2 genes, mutations of which can signal a high risk of breast and ovarian cancer.
But Gene by Gene will be able to continue to offer those tests outside the U.S., as well as selling worldwide products and services linked to the whole genome and portions called exomes that include BRCA tests.
The settlement "is in the best interest of the parties because it ends the uncertainty and expense of ongoing litigation," Myriad spokesman Ron Rogers said in a statement. "Additionally, this deal clears the way for GbG to conduct whole genome and exome...
Myriad Genetics said Friday it had reached a settlement with Houston-based Gene by Gene Ltd., but Myriad vowed to continue legal battles against other competitors trying to jump into the market.
As part of the settlement, Gene by Gene will stop selling or marketing tests in the United States for the BRCA1 and BRCA2 genes, mutations of which can signal a high risk of breast and ovarian cancer.
But Gene by Gene will be able to continue to offer those tests outside the U.S., as well as selling worldwide products and services linked to the whole genome and portions called exomes that include BRCA tests.
The settlement "is in the best interest of the parties because it ends the uncertainty and expense of ongoing litigation," Myriad spokesman Ron Rogers said in a statement. "Additionally, this deal clears the way for GbG to conduct whole genome and exome...